Literature DB >> 30573532

Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma.

Cindy Pabon1, Ashwini K Esnakula2, Karen Daily3.   

Abstract

A middle-aged woman with a history of leiomyosarcoma of the uterus treated with surgery and adjuvant chemotherapy suffered a bulky metastatic recurrence 1 year later. She elected treatment with palliative eribulin, presenting with acute renal failure and electrolyte abnormalities consistent with tumour lysis syndrome on cycle 1 day 8. Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chemotherapy; gynecological cancer; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 30573532      PMCID: PMC6303597          DOI: 10.1136/bcr-2018-224576

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

Authors:  Patrick Schöffski; Isabelle Laure Ray-Coquard; Angela Cioffi; Nguyen Bin Bui; Sebastian Bauer; Joerg Thomas Hartmann; Anders Krarup-Hansen; Viktor Grünwald; Raf Sciot; Herlinde Dumez; Jean-Yves Blay; Axel Le Cesne; Jantien Wanders; Carolyn Hayward; Sandrine Marreaud; Monia Ouali; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2011-09-19       Impact factor: 41.316

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

3.  A case of tumor lysis syndrome following chemotherapy for a uterine epithelioid leiomyosarcoma with focal rhabdomyosarcomatous differentiation.

Authors:  Yoshie Hiraizumi; Seiryu Kamoi; Yusuke Inde; Keisuke Kurose; Yoshiharu Ohaki; Toshiyuki Takeshita
Journal:  J Obstet Gynaecol Res       Date:  2011-03-16       Impact factor: 1.730

Review 4.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 5.  Tumor Lysis Syndrome: A Unique Solute Disturbance.

Authors:  Penelope Z Strauss; Shannan K Hamlin; Johnny Dang
Journal:  Nurs Clin North Am       Date:  2017-04-07       Impact factor: 1.208

6.  Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Authors:  Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

Review 7.  Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature.

Authors:  P Drakos; J Bar-Ziv; R Catane
Journal:  Am J Clin Oncol       Date:  1994-12       Impact factor: 2.339

8.  Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.

Authors:  L Baeksgaard; J B Sørensen
Journal:  Cancer Chemother Pharmacol       Date:  2003-02-28       Impact factor: 3.333

9.  Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.

Authors:  Akira Kawai; Nobuhito Araki; Yoichi Naito; Toshifumi Ozaki; Hideshi Sugiura; Yasuo Yazawa; Hideo Morioka; Akihiko Matsumine; Kenichi Saito; Shun Asami; Kazuo Isu
Journal:  Jpn J Clin Oncol       Date:  2017-02-01       Impact factor: 3.019

10.  Spontaneous Tumor Lysis Syndrome due to Uterine Leiomyosarcoma with Lung Metastases.

Authors:  Vivek Alaigh; Debapriya Datta
Journal:  Case Rep Crit Care       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.